

National Institutes of Health Workshop: ***“Psychedelics as Therapeutics; Gaps, Challenges & Opportunities.”*** January 12-13, 2022. (All times are Eastern Standard Time)

Agenda and Speaker Titles

Day 1

9:00 AM **Joshua Gordon (NIMH)** *Directors Welcome and Opening remarks.*

9:30-10:15 **Franz Vollenweider** (University of Zurich): *Neurobiology of psychedelic drug effects on self-processing, affect, and social cognition: implications for potential therapeutic change.*

Theme 1: **Basic and Translational Research**

10:15 *Introduction to basic and translational research theme.*

10:20 **Gabriella Gobbi** (McGill University): *Psychedelics for mental health: translating preclinical data into clinical practice.*

10:40 **Bryan Roth** (University North Carolina): *The promises and perils of psychedelic pharmacology.*

Break 11:00 to 11:15

11:15 **Clint Canal** (Mercer University): *How informative are preclinical models of psychedelic drug mechanisms? From 5-HT_{2A} to another place far away.*

11:35 **Scott Thompson** (University of Maryland): *Optimizing psychedelics for treating neuropsychiatric disease: the preclinical perspective.*

11:55 **Gitte Knudsen** (University of Copenhagen): *5-HT_{2AR} PET imaging and functional connectivity as biomarkers of target engagement.*

12:15-1:00

PANEL

Franz, Gabriella, Bryan, Clint, Scott, Gitte. **Rob Malenka** (Stanford University) as discussant (10 min)

1:00 PM

Closeout

National Institutes of Health Workshop: ***“Psychedelics as Therapeutics; Gaps, Challenges & Opportunities.”***

Day 2

Theme 2: **Clinical Trials**

9:30 AM *Introduction to clinical trials theme.*

9:35 **Michael Mithoefer** (Medical University South Carolina): *MDMA trial design, what have we learned?*

9:55 **Michael Bogenschutz** (New York University): *Does subjective experience mediate the putative therapeutic effects of psychedelics?*

10:15 **Jennifer Mitchell** (University of California San Francisco): *Safety and efficacy of MDMA for the treatment of PTSD.*

10:35 **Matthew Johnson** (Johns Hopkins University): *Psilocybin and smoking cessation.*

10:55 **Celia Morgan** (University of Exeter): *Ketamine assisted psychotherapy in the treatment of alcohol use disorder and other addictions.*

11:15-12:00 **PANEL**

Michael M, Michael B, Jennifer, Matthew, Celia. **Elias Dakwar** (Columbia University) as discussant (10 min)

12:00-12:30 Lunch

Theme 3: **Optimizing Future Clinical Trial Designs**

12:30 PM *Introduction to optimizing future clinical trial designs.*

12:35 **Ido Hartogsohn**, (Bar-Ilan University): *Set and Settings in psychedelic clinical trials and moving forward.*

12:55 **Suresh Muthukumaraswamy** (University of Auckland): *Overcoming confounds in psychedelic clinical trials: designs and measurement.*

1:15 **Paul Appelbaum** (Columbia University): *Ethical considerations in conducting psychedelic research.*

1:40 **Javier Muniz** (FDA): *Considerations of study design and interaction of medication and medical practice in drug registration trials.*

2:10-2:55 **PANEL**

Ido, Suresh, Paul, Javier, **Susan Learned** (Independent Pharmaceutical Consultant) as discussant (10 min)

2:55 PM **Nora Volkow (NIDA):** *Directors summation and Closing remarks*